Roche (ROG: SIX) subsidiary Genentech has provided an update on its multiple sclerosis program, revealing a partial trial stoppage for the oral BTK inhibitor fenebrutinib.
The US Food and Drug Administration has stopped enrollment in the Phase III FENhance I trial, after two recent cases of elevated liver enzymes were discovered.
Genentech said the data were “suggestive of drug-induced liver injury,” a worry that has affected rival BTK blockers under development by Sanofi (Euronext: SAN) and Merck KGaA (MRK: DE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze